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participate.Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality 1111Jolanta M. Siller-Matula, Dietmar Trenk, Karsten Schrör, Meinrad Gawaz, Steen D. Kristensen,
Robert F. Storey, Kurt Huber, for the EPA (European Platelet Academy)
P2Y12 inhibitors are widely used in the secondary prevention of thrombotic events.
High on-treatment platelet reactivity (HTPR) in clopidogrel-treated patients led to
the development of the more effective platelet P2Y12 inhibitors prasugrel and
ticagrelor, which provide more consistent and more potent platelet inhibition than
clopidogrel. The current review focuses on use of platelet function testing and
pharmacogenomic testing in order to identify patients who do not respond sufﬁ-
ciently to P2Y12 inhibitors and discusses trials, which so far have failed to show that
tailored antiplatelet therapy improves clinical outcome.JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.MINI-FOCUS ON
RADIAL ACCESSRisk Score, Causes, and Clinical Impact of Failure of Transradial Approach
for Percutaneous Coronary Interventions1129Eltigani Abdelaal, Cynthia Brousseau-Provencher, Sarah Montminy, Guillaume Plourde,
Jimmy MacHaalany, Yoann Bataille, Pierre Molin, Jean-Pierre Déry, Gérald Barbeau,
Louis Roy, Éric Larose, Robert De Larochellière, Can M. Nguyen, Guy Proulx,
Olivier Costerousse, Olivier F. Bertrand, for the Interventional Cardiologists
at Quebec Heart-Lung Institute
The authors sought to determine causes of, and to develop a risk score for failure of
transradial approach (TRA) for percutaneous coronary interventions (PCI). TRA-
PCI was attempted in 1,609 (97.3%) patients, while 45 (2.7%) patients had primary
TRA-PCI failure. Crossover TRA-PCI failure occurred in 30 (1.8%) patients.
Causes of primary TRA-PCI failure included chronic radial artery occlusion,
previous CABG, and cardiogenic shock. Causes of crossover TRA-PCI failure
included inadequate puncture, radial spasm, radial loop, subclavian tortuosity, and
inadequate guide catheter support. Female sex (OR: 3.2), previous CABG (Odds
Ratio [OR]: 6.1) and cardiogenic shock (OR: 11.2) were independent predictors of
TRA-PCI failure. Risk score values from 0 to 7 predicted a TRA-PCI failure rate
from 2% to 80%.(continued on A-29)
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A-29A Randomized Comparison of the Transradial and Transfemoral Approaches
for Coronary Artery Bypass Graft Angiography and Intervention: The RADIAL-CABG
Trial (RADIAL Versus Femoral Access for Coronary Artery Bypass Graft
Angiography and Intervention)1138Tesfaldet T. Michael, Mohammed Alomar, Aristotelis Papayannis, Owen Mogabgab,
Vishal G. Patel, Bavana V. Rangan, Michael Luna, Jeffrey L. Hastings, Jerrold Grodin,
Shuaib Abdullah, Subhash Banerjee, Emmanouil S. Brilakis
The authors performed a randomized, controlled trial of radial versus femoral access
among 128 patients who had previously undergone coronary artery bypass graft
surgery undergoing cardiac catheterization. Compared with femoral access, diag-
nostic coronary angiography via radial access was associated with higher mean
contrast volume, longer procedure time, and greater patient air kerma radiation
exposure, and greater operator radiation exposure. The incidences of the primary
and secondary endpoints were similar with femoral and radial access among patients
undergoing percutaneous coronary intervention. Access crossover was higher in the
radial access group (17.2% vs. 0.0%, p < 0.01), and vascular access site complica-
tions were similar in both groups.Systematic Use of Transradial PCI in Patients With ST-Segment Elevation
Myocardial Infarction: A Call to “Arms”1145Mackram F. Eleid, Charanjit S. Rihal, Rajiv Gulati, Malcolm R. Bell
Growing evidence supports the use of transradial percutaneous intervention (TRI)
as the preferred access site for the treatment of patients with ST-segment elevation
myocardial infarction (STEMI). TRI is associated with reduced periprocedural
bleeding and lower mortality compared with transfemoral access in the STEMI
population. Despite the evidence, trends in use of TRI have shown a slow adoption
rate as a result of multiple barriers in clinical practice. We summarize the current
evidence and propose a call to action to foster training of TRI in cardiovascular
fellowship programs and post-fellowship courses, and for more widespread imple-
mentation of TRI in STEMI patients.Transradial Versus Transfemoral Percutaneous Coronary Intervention
in Acute Coronary Syndromes: Re-Evaluation of the Current Body of Evidence1149Michael S. Lee, Michael Wolfe, Gregg W. Stone
Clinical trials demonstrated lower rates of bleeding and vascular complications with
transradial intervention (TRI) compared with transfemoral intervention (TFI) in
acute coronary syndrome. Bleeding is a major independent predictor of death. The
dose of heparin and percent of patients on glycoprotein IIb/IIIa inhibitors in these
trials were unnecessarily high, and there was a paucity of patients on bivalirudin.
These trials were also conducted in high-volume transradial centers, further limiting
the ability to generalize the ﬁndings. An optimally designed trial comparing TRI
with TFI in patients on bivalirudin, potent oral antiplatelet medication, and without
adjunctive glycoprotein IIb/IIIa inhibitors is needed to assess outcomes on the basis
of access site alone.(continued on A-30)
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A-30The Role of Drug-Eluting Balloons Alone or in Combination With Drug-Eluting Stents
in the Treatment of De Novo Diffuse Coronary Disease1153Charis Costopoulos, Azeem Latib, Toru Naganuma, Alessandro Sticchi, Filippo Figini,
Sandeep Basavarajaiah, Mauro Carlino, Alaide Chieffo, Matteo Montorfano, Charbel Naim,
Masanori Kawaguchi, Francesco Giannini, Antonio Colombo
Data on the use of drug-eluting balloons (DEB) for diffuse coronary artery disease
(CAD) (>25 mm) are limited. Sixty-nine patients (93 lesions) were treated with
DEB; 56% of lesions were treated with only DEB; 7.4% with DEB and drug-
eluting stents (DES) as bail out; and 36.6% with both DESs and DEB as part of an
approach for very long disease. Results were compared with those of a similar cohort
of patients treated with DES alone. Outcome rates at 2 years for major adverse
cardiac events and target vessel revascularization with DEB were similar to those
treated with DES alone (20.8% vs. 22.7%, p ¼ 0.738 and 14.8% vs. 11.5%, p ¼
0.436) suggesting that DEB may have a role in the treatment of diffuse coronary
disease.Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation
Lesions: The Nordic Stent Technique Study 36-Month Follow-Up Results1160Kari Kervinen, Matti Niemelä, Hannu Romppanen, Andrejs Erglis, Indulis Kumsars,
Michael Maeng, Niels R. Holm, Jens F. Lassen, Pål Gunnes, Sindre Stavnes, Jan S. Jensen,
Anders Galløe, Inga Narbute, Dace Sondore, Evald H. Christiansen, Jan Ravkilde,
Terje K. Steigen, Jan Mannsverk, Per Thayssen, Knud Nørregaard Hansen,
Steffen Helqvist, Saila Vikman, Rune Wiseth, Jens Aarøe, Jari Jokelainen, Leif Thuesen,
for the Nordic PCI Study Group
This randomized study compared the long-term clinical outcomes after treatment of
coronary artery bifurcations with the crush or the culotte stent technique. At 36
months, the rates of the primary composite endpoint of cardiac death, myocardial
infarction, and target vessel revascularization were similar after crush or culotte
stenting: 20.6% versus 16.7% (p ¼ 0.32), respectively.
See additional content in the online version of this issue.(continued on A-31)
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A-31Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms
in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients
With Stable Coronary Artery Disease1166Chiara Viviani Anselmi, Carlo Briguori, Roberta Roncarati, Laura Papa,
Gabriella Visconti, Amelia Focaccio, Francesca De Micco, Michael V. G. Latronico,
Paolo Pagnotta, Gianluigi Condorelli
This study assessed genotyping and on-treatment platelet reactivity, measured with
the VerifyNow P2Y12 test (Accumetrics Inc., San Diego, California), as predictors
of major adverse cardiac events in patients with stable coronary artery disease
receiving drug-eluting stents under clopidogrel treatment. We found that: 1) loss-
of-function variants of CYP2C19 had signiﬁcant hazard ratios for major adverse
cardiac events; and 2) measuring on-treatment platelet reactivity was clinically
signiﬁcant only in patients copresenting with diabetes or chronic kidney disease.
Thus, assessment of CYP2C19 polymorphisms can be used routinely to risk-stratify
stable coronary artery disease patients receiving drug-eluting stents, whereas the
VerifyNow test has a predictive value only in high-risk subsets.
See additional content in the online version of this issue.Long-Term Experience and Outcomes With Transcatheter Closure of
Patent Foramen Ovale1176Ignacio Inglessis, Sammy Elmariah, Pablo A. Rengifo-Moreno, Ronan Margey,
Caitlin O’Callaghan, Ignacio Cruz-Gonzalez, Suzanne Baron, Praveen Mehrotra,
Timothy C. Tan, Judy Hung, Zareh N. Demirjian, Ferdinando S. Buonanno,
MingMing Ning, Scott B. Silverman, Roberto J. Cubeddu, Eugene Pomerantsev,
Robert M. Schainfeld, G. William Dec, Jr, Igor F. Palacios
The clinical implications of patent foramen ovale (PFO) have been unclear and
driven substantial debate within the ﬁeld of cardiovascular medicine. We report the
outcomes of 800 consecutive patients who underwent PFO closure at our institution
after multidisciplinary evaluation over a 16-year period. Transcatheter PFO closure
was performed overwhelmingly for cryptogenic cerebrovascular events. The recur-
rence rate for ischemic neurologic events during long-term follow-up is remarkably
low after PFO closure regardless of closure device type.EDITORIAL COMMENTClosure of the Patent Foramen Ovale: Because We Can, Should We?
and in Whom?1184Robert N. Piana, Howard S. Kirshner(continued on A-32)
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A-32Fluoroscopic Guide to an Ideal Implant Position for Sapien XT and CoreValve
During a Valve-in-Valve Procedure1186Vinnie N. Bapat, Rizwan Q. Attia, Fortunata Condemi, Ravi Visagan, Maya Guthrie,
Shelina Sunni, Martyn Thomas
Transcatheter heart valves (THV) are increasingly used to treat degenerated surgical
heart valves (SHV). This novel treatment is promising and less invasive. Securing
the THV in an optimal position within the SHV is important. Understanding the
structure and ﬂuoroscopic appearances of various SHV and both THV provides
a platform in achieving an optimal result during a valve-in-valve (VIV) procedure.
This paper discusses the ﬂuoroscopic relationship between various VIV combina-
tions, provides a ﬂuoroscopic guide to an optimal positioning of the THV within
various commercially available SHV, and examines whether circularity of the THV
is maintained after a VIV implantation.Transcatheter Aortic Valve Implantation Reduces Sympathetic Activity and
Normalizes Arterial Spontaneous Baroreﬂex in Patients With Aortic Stenosis1195Nicolas Dumonteil, Angelica Vaccaro, Fabien Despas, Marc Labrunee, Bertrand Marcheix,
Elisabeth Lambert, Murray Esler, Didier Carrie, Jean-Michel Senard, Michel Galinier,
Atul Pathak
Effects of transcatheter aortic valve implantation (TAVI) on the sympathetic
nervous system are unknown. We compared muscle sympathetic nerve activity
(MSNA) in 14 patients with aortic stenosis (AS) before and after TAVI and in 14
control patients. All patients underwent MSNA and arterial baroreﬂex gain
assessment at baseline and after TAVI. Patients with AS had a higher MSNA (61.0
 1.7 burst/min vs. 55.4  1.4 burst/min; p < 0.05) and a lower arterial baroreﬂex
gain (2.13  0.14% burst/mm Hg vs. 3.32  0.19% burst/mm Hg; p < 0.01) than
controls. TAVI induced a signiﬁcant decrease in MSNA (61.0  1.7 burst/min to
54.1  1.0 burst/min; p < 0.01) and an increase in arterial baroreﬂex gain (2.13 
0.14% burst/mm Hg to 3.49  0.33% burst/mm Hg; p < 0.01).(continued on A-33)
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A-33Randomized Comparison of Distal and Proximal Cerebral Protection During
Carotid Artery Stenting1203Manuel N. Cano, Antônio M. Kambara, Silvia J. F. de Cano, Luiz Antônio Pezzi Portela,
Ângela Tavares Paes, J. Ribamar Costa, Jr, Alexandre Antônio Cunha Abizaid,
Samuel Martins Moreira, Amanda G. M. R. Sousa, J. Eduardo Moraes Rego Sousa
A total of 60 patients with signiﬁcant carotid artery disease and suitable anatomy for
carotid artery stenting (CAS) were randomly assigned to be treated with distal
(ANGIOGUARD, Cordis Corporation, Bridgewater, New Jersey) or proximal
(Mo.Ma Ultra, Invatec/Medtronic Vascular Inc, Santa Rosa, California) cerebral
protection devices. All patients underwent diffusion-weighted magnetic resonance
imaging (DW-MRI) before and after CAS. New ischemic lesions seen on DW-
MRI were present in both groups in >60%, but the number of lesions per patient
was greater in the ANGIOGUARD group. There was no death or disabling stroke
during at least 1 year of follow-up in both cohorts.IMAGES IN
INTERVENTIONColocalization of Low and Oscillatory Coronary Wall Shear Stress With
Subsequent Culprit Lesion Resulting in Myocardial Infarction in an
Orthotopic Heart Transplant Patient1210Lucas H. Timmins, Benjamin D. Mackie, John N. Oshinski, Don P. Giddens, Habib Samady
This article has accompanying videos that can be viewed in the online
version of this issue.Percutaneous Transluminal Pulmonary Angioplasty for Central-Type
Chronic Thromboembolic Pulmonary Hypertension1212Haruhisa Ishiguro, Masaharu Kataoka, Takumi Inami, Ryoji Yanagisawa, Nobuhiko Shimura,
Hiroki Taguchi, Hideyasu Kohshoh, Hideaki Yoshino, Toru Satoh
This article has accompanying videos that can be viewed in the online
version of this issue.(continued on A-34)
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A-34LETTERS TO
THE EDITORPrevention of Radial Artery Spasm: Importance of a Multifactorial Approach 1214Adel Aminian, Jacques Lalmand, Dariouch DolatabadiAnxiety Score as a Risk Factor for Radial Artery Spasm During
Transradial Procedures1214Suleyman Ercan, Vedat Davutoglu, Murat YuceREPLYSpyridon Deftereos, Georgios GiannopoulosEDITOR’S PAGE Affordable Care: Why Not Also Affable? 1216Spencer B. King III
